There is a high incidence of non-Hodgkin's lymphoma in patients with impaired cell-mediated immunity, including patients with congenital immunodeficiency and iatrogenically immunosuppressed allogeneic transplant recipients. A significantly increased incidence of lymphoma has also been demonstrated in HIV infected patients and within this group the prevalence is rising. This rise reflects not only the increasing number of people infected with the HIV virus, but also their improved survival as a consequence of advances in antiretroviral therapy and the more effective management of opportunistic infections. The HIV-associated lymphomas (HAL) form two groups of different histology, prognosis and pathogenesis; the Burkitt's lymphomas, and the diffuse large cell and immunoblastic lymphomas. This review will focus on the molecular biology of these lymphomas.
Burkitt's lymphoma
Approximately a third of HIV-associated lymphomas are small non-cleaved cell Burkitt-like lymphomas (Ziegler et al., 1984; Knowles et al., 1988; Lowenthal et al., 1988; Roithmann et al., 1991 (Pellici et al., 1986) . In endemic BL which is consistenly associated with Epstein-Barr virus (EBV), breaks occur up to 75 kB 5' (upstream) of the c-myc oncogene; in sporadic BL most of the translocations occur around exon-1 of c-myc (Shiramizu et al., 1991) . Although these latter breakpoints alter the c-myc RNA transcript, the region affected is untranslated and so the amino acid sequence of the myc protein is unchanged. The overall consequence of both rearrangements is increased expression of myc protein rather than a qualitative change. Myc (Coppola & Cole, 1986; Prochnownik & Kukowska, 1986 .
The geographic association with malaria and the frequent presence of EBV genome within tumour cells are found in endemic BL, but not in either sporadic BL or HIV-associated BL. Endemic malaria leads to hyperstimulation of the humoural immune system and secondary suppression of cell mediated immunity. HIV infection induces a vigorous immune response with a 10-fold increase in polyclonal immunoglobulin production. Polyclonal B cell activation by HIV may be a direct mitogenic effect or may be antigenspecific (Schnittman et al., 1986) . Parasite induced T cell immunosuppression and polyclonal B-cell activation are thus features of both HIV and malaria infection and suggests that HIV infection may be performing an analogous role to holoendemic malaria in the pathogenesis of BL. The predominance of sporadic BL in HIV infection rather than endemic BL reflects the stage of B-cell ontotogony at which chromosome rearrangement errors take place. In general errors occur during VHDHJH recombination in the presence of EBV (eBL) but occur later during isotype class switching in the absence of EBV (sBL).
A further potential mechanism in the pathogenesis of HIV associated BL involves interleukin-6 secretion by HIV infected macrophages. Interleukin-6 is a B cell stimulatory factor which enhances the growth of EBV transformed lym-phoblastoid cell lines in vitro and may therefore have a role in the development of BL. Other factors that have been identified as possible agents in this process include mutations of the tumour suppressor gene p53 (Giadano et al., 1991) and secondary non-random chromosomal abnormalities of band 13q34 (Berger et al., 1989 (Cleary et al., 1988b) . In addition, EBV has an aetiological role in the development of several other diseases in the immunocomprised patient. Primary EBV infection in HIV infected children is thought to cause lymphocytic interstitial pneumonitis (Andiman et al., 1985) and replicative lysogenic cycle EBV is implicated in the development of hairy leukoplakia in HIV infected patients (Greenspan et al., 1985 (Purtilo & Grierson, 1991) and allograft recipients, there is a decrease in cytotoxic T-cell activity against EBV and these patients develop lymphomas containing EBV. A similar reduction of the cytotoxic T lymphocytes mediated suppression of EBV induced antibody secretion in vitro, and increased circulating cells containing EBV in vivo has been demonstrated in HIV infected patients (Birx et al., 1986) . This loss of cell mediated control of EBV is progressive, and as CD4 levels fall there is a concomitant rise in the incidence of IB and LCL lymphomas.
EBV has been detected by DNA in situ hybridisation in about 30-50% of these HIV associated LCL and IB lymphomas although there appears to be regional variation with higher rates reported from New York than San Francisco (Cremer et al., 1990) , which may relate to the low sensitivity of this methodology. Viral (Ng et al., 1989) . Furthermore, NG described a patient with HAL whose tumour secreted a monoclonal paraprotein directed at the gp 160 antigen of HIV (Ng et al., 1990) . It would appear that in this instance HIV is playing a role in lymphomagenesis by antigen specific B cell activation. Herndier has recently described a high grade lymphoma in a patient with AIDS which demonstrated both genotypc (T-cell receptor P-chain gene rearrangement) and immunophenotypic (CD4 +, CD5 + CD45RO+) features of T-cell lymphoma. The tumour expressed interleukin 2 receptor (IL-2R) and produced both IL-2 and IL-2R RNA transcripts analogous to HTLV-1 associated adult T-cell leukaemia/lymphoma (ATLL) but without detectable HTLV-1 or EBV. Southern blot analysis showed monoclonally integrated HIV-1 in the tumour genome and immunocytochemistry demonstrated HIV p24 antigen in tumour cells. In this rare T-cell HAL HIV appears to be implicated in lymphomagenesis althought the mechanism remains uncertain. HIV integration may occur at or near cellular oncogenes leading to deregulated expression and cell transformation. Alternatively the HIV tat gene product may stimulate IL-2 production, and the presence of IL-2R on tumour cells may complete an autocrine loop stimulating tumour proliferation (Herndier et al., 1992) .
Transplantation-associated lymphomas and HAL both express EBV latent cycle antigens and the tumours are therefore susceptible to cell-mediated immunity. Following transplantation T-cell function is suppressed to reduce graft rejection, and a reduction in this immunosuppressive therapy may lead to regression of transplantation-associated lymphomas (Starzl et al., 1984) . This therapeutic option is not available to AIDS patients, and the very poor outlook for these HAL patients brings into question the value of any treatments other than symptom palliation. In contrast HIV infected patients with BL have a higher remission rate and longer median survival, including a few documented survivors at 3 years (Roithmann et al., 1991) . 
